- Synthesis method of semetinib
-
The invention relates to a synthesis method of simetinib. According to the method, diethoxymethane is creatively adopted as a ring closing reactant, and two-step reaction of ring closing reaction and methylation is combined into one step, so the yield is
- -
-
-
- Method for preparing semetinib
-
The invention relates to a method for preparing an MEK1/2 inhibitor smeltinib, which comprises the following steps: carrying out three-step reaction on the synthetic route to synthesize the smeltinib, carrying out post-treatment on the synthetic method wi
- -
-
Paragraph 0057-0063
(2021/04/21)
-
- INTERMEDIATES OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MAP2K OR MEK) INHIBITORS AND PROCESS FOR THEIR PREPARATION
-
The present invention relates to intermediates of Mitogen-activated protein kinase kinase (MAP2K or MEK) inhibitors such as Selumetinib, Binimetinib and process for their preparation. The present invention also relates to process for the 5 preparation of MEK inhibitors such as Selumetinib, and Binimetinib.
- -
-
Page/Page column 12
(2018/04/21)
-
- NOVEL HYDROGEN SULFATE SALT
-
The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I
- -
-
Page/Page column 21-22
(2008/06/13)
-
- N3 alkylated benzimidazole derivatives as MEK inhibitors
-
Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
- -
-
-